An exploration of LAF‐bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non—small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14696
Abstract: Immune checkpoint inhibitor (ICI) combined with chemotherapy is one of the standards of care for advanced non–small cell lung cancer (NSCLC) without driver mutations. However, the biomarker of combination therapy is still unknown. Although previous… read more here.
Keywords: non small; efficacy; combined chemotherapy; laf btmb ... See more keywords